Literature DB >> 33186060

Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation.

Erin C Taylor1, Lina Irshaid1, Mahan Mathur1.   

Abstract

Ovarian neoplasms can be categorized on the basis of histopathologic features into epithelial surface cell tumors, germ cell tumors, sex cord-stromal tumors, and metastases. While their imaging appearance is often nonspecific, it closely parallels the gross pathologic appearance, and radiologic-pathologic correlation is helpful to aid in a deeper understanding of the subtypes. Epithelial cell neoplasms are the most common category, and they can be benign, borderline, or malignant. Specific subtypes include serous (most common), mucinous, seromucinous, endometrioid, clear cell, Brenner, and undifferentiated. High-grade serous cystadenocarcinoma accounts for the majority of malignant ovarian tumors and the most ovarian cancer deaths. While serous neoplasms are often unilocular and bilateral, mucinous neoplasms are larger, unilateral, and multilocular. Solid components, thickened septa, and papillary projections, particularly with vascularity, indicate borderline or malignant varieties. Endometrioid and clear cell carcinomas can arise within endometriomas. Fibrous tumors (cystadenofibroma, adenofibroma, fibroma or fibrothecoma, and Brenner tumors) demonstrate low T2-weighted signal intensity of their solid components, while teratomas contain lipid. The nonspecific imaging appearance of additional malignant ovarian germ cell tumors can be narrowed with tumor marker profiles. Sex cord-stromal tumors are often solid, and secondary signs from their hormonal secretion can be a clue to their diagnosis. The authors review the anatomy of the ovary and distal fallopian tube, the proposed origins of the histologic subtypes of tumors, the clinical features and epidemiology of ovarian neoplasms, and the applications of US, CT, and MRI in imaging ovarian neoplasms. The main focus is on the radiologic and pathologic features of the multiple ovarian neoplasm subtypes. An algorithmic approach to the diagnosis of ovarian neoplasms is presented. Online supplemental material is available for this article. ©RSNA, 2020.

Entities:  

Year:  2020        PMID: 33186060     DOI: 10.1148/rg.2021200086

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  6 in total

Review 1.  Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice.

Authors:  Ayumi Ohya; Yasunari Fujinaga
Journal:  Jpn J Radiol       Date:  2022-08-02       Impact factor: 2.701

2.  Interreader Agreement and Intermodality Concordance of O-RADS US and MRI for Assessing Large, Complex Ovarian-Adnexal Cysts.

Authors:  Yang Guo; Catherine H Phillips; Krista Suarez-Weiss; Lauren A Roller; Mary C Frates; Carol B Benson; Atul B Shinagare
Journal:  Radiol Imaging Cancer       Date:  2022-09

3.  Schwannoma mimicking ovarian malignancy.

Authors:  Inês Conde Vasco; Gonçalo Martins Pereira; Joana Ferreira; Teresa Margarida Cunha
Journal:  Radiol Case Rep       Date:  2022-09-14

4.  Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report.

Authors:  Yiying Tao; Lei Tang; Li Zuo; Yue Ma; Fengchun Zhang; Yingchun Xu
Journal:  Oncol Lett       Date:  2022-08-17       Impact factor: 3.111

5.  Spectral CT in peritoneal carcinomatosis from ovarian cancer: a tool for differential diagnosis of small nodules?

Authors:  Giada Zorzetto; Andrea Coppola; Valeria Molinelli; Maria Gloria Angeretti; Jvan Casarin; Federico Fontana; Filippo Piacentino; Giulio Carcano; Fabio Ghezzi; Massimo Venturini
Journal:  Eur Radiol Exp       Date:  2022-10-17

Review 6.  Serous borderline ovarian tumours: an extensive review on MR imaging features.

Authors:  Hilal Sahin; Asli Irmak Akdogan; Janette Smith; Jeries Paolo Zawaideh; Helen Addley
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.